Ivermectin ‘makes no clinical difference’ in COVID-19: major trial
Early intervention with the much-touted drug fails to keep high-risk patients out of hospital or shorten recovery times, researchers say
High-dose ivermectin treatment of symptomatic patients early in their COVID-19 illness doesn’t reduce the risk of hospital admission, according to one of the largest randomised trials of the antiparasitic to date.
The international TOGETHER trial found no clinical advantage in using the drug.
